Triterpenoid resinous metabolites from the genus Boswellia: Pharmacological activities and potential species-identifying properties

Chemistry Central Journal

Volumn 7, Issue 1, 2013, Pages

  Zhang, Yuxin ^a   Ning, Zhangchi ^a   Lu, Cheng ^b   Zhao, Siyu ^a   Wang, Jianfen ^a   Liu, Baoqin ^c   Xu, Xuegong ^c   Liu, Yuanyan ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^c Traditional Chinese Medicine Hospital   (China)

Author keywords

Anti carcinogenic; Anti inflammation; Bioavailability; Boswellia; Pharmacological activities; Triterpenoids

Indexed keywords

EID: 84883730063     PISSN: None     EISSN: 1752153X     Source Type: Journal    
DOI: 10.1186/1752-153X-7-153     Document Type: Review

References (127)

1. Modugno F, Ribechini E, Colombini MP. Chemical study of triterpenoid resinous materials in archaeological findings by means of direct exposure electron ionisation mass spectrometry and gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2006, 20:1787-1800. 10.1002/rcm.2507, 16676320.
2. Lemenih M, Teketay D. Frankincense and myrrh resources of Ethiopia: II. Medicinal and industrial uses. Sinet 2003, 26:161-172.
3. Siddiqui M. Boswellia serrata, a potential antiinflammatory agent: an overview. Indian J Pharmaceut Sci 2011, 73:255.
4. Tadesse W, Desalegn G, Alia R. Natural gum and resin bearing species of Ethiopia and their potential applications. Investigación agraria. Sistemas y recursos forestales 2007, 16:211-221.
5. Krieglstein CF, Anthoni C, Rijcken EJM, Laukötter M, Spiegel HU, Boden SE, Schweizer S, Safayhi H, Senninger N, Schürmann G. Acetyl-11-keto-β-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis 2001, 16:88-95. 10.1007/s003840100292, 11355324.
6. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet 2011, 50:349-369. 10.2165/11586800-000000000-00000, 21553931.
7. Choudhary MI, Sondengam B, Makhmoor T, Yasin A, Fatima N, Ngounou F, Kimbu S, Naz H, Atta-ur-Rahman, Fadimatou. Bioactive Constituents from Boswellia papyrifera. J Nat Prod 2005, 68:189-193. 10.1021/np040142x, 15730241.
8. Lu M, Xia L, Hua H, Jing Y. Acetyl-Keto-β-Boswellic Acid Induces Apoptosis through a Death Receptor 5-Mediated Pathway in Prostate Cancer Cells. Cancer Res 2008, 68:1180-1186. 10.1158/0008-5472.CAN-07-2978, 18281494.
9. Estrada AC, Syrovets T, Pitterle K, Lunov O, Büchele B, Schimana-Pfeifer J, Schmidt T, Morad SAF, Simmet T. Tirucallic acids are novel pleckstrin homology domain-dependent Akt inhibitors inducing apoptosis in prostate cancer cells. Mol Pharmacol 2010, 77:378-387. 10.1124/mol.109.060475, 20018812.
10. Bhushan S, Malik F, Kumar A, Isher HK, Kaur IP, Taneja SC, Singh J. Activation of p53/p21/PUMA alliance and disruption of PI-3/Akt in multimodal targeting of apoptotic signaling cascades in cervical cancer cells by a pentacyclic triterpenediol from Boswellia serrata. Mol Carcinog 2009, 48:1093-1108. 10.1002/mc.20559, 19544329.
11. Suhail MM, Wu W, Cao A, Mondalek FG, Fung KM, Shih PT, Fang YT, Woolley C, Young G, Lin HK. Boswellia sacra essential oil induces tumor cell-specific apoptosis and suppresses tumor aggressiveness in cultured human breast cancer cells. BMC Complement Altern Med 2011, 11:129. 10.1186/1472-6882-11-129, 3258268, 22171782.
12. Yadav VR, Prasad S, Sung B, Gelovani JG, Guha S, Krishnan S, Aggarwal BB. Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers. Int J Cancer 2011, 130:2176-2184. 3246525, 21702037.
13. Park B, Prasad S, Yadav V, Sung B, Aggarwal BB. Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets. PLoS One 2011, 6:e26943. 10.1371/journal.pone.0026943, 3204996, 22066019.
14. Frank M, Yang Q, Osban J, Azzarello J, Saban M, Saban R, Ashley R, Welter J, Fung KM, Lin HK. Frankincense oil derived from Boswellia carteri induces tumor cell specific cytotoxicity. BMC Complement Altern Med 2009, 9:6. 10.1186/1472-6882-9-6, 2664784, 19296830.
15. Thulin M, Warfa A. The frankincense trees (Boswellia spp., Burseraceae) of northern Somalia and southern Arabia. Kew Bull 1987, 42(3):487-500.
16. Duperon J. L'encens et les Boswellia: historique. Apport de l'anatomie à la systématique de trois Boswellia de Somalie et du Yemen. Revue de cytologie et de biologie végétales Le Botaniste 1993, 16:185-209.
17. Archier P, Vieillescazes C. Characterization of various geographical origin incense based on chemical criteria. Analusis 2000, 28:233-237.
18. Mathe C, Culioli G, Archier P, Vieillescazes C. Characterization of archaeological frankincense by gas chromatography-mass spectrometry. J Chromatogr A 2004, 1023:277-285. 10.1016/j.chroma.2003.10.016, 14753694.
19. Paul M, Brüning G, Bergmann J, Jauch J. A Thin-layer Chromatography Method for the Identification of Three Different Olibanum Resins (Boswellia serrata, Boswellia papyrifera and Boswellia carterii, respectively, Boswellia sacra). Phytochem Anal 2011, 23:184-189.
20. Hepper FN. Arabian and African frankincense trees. J Egypt Archaeol 1969, 55:66-72.
21. Büchele B, Zugmaier W, Simmet T. Analysis of pentacyclic triterpenic acids from frankincense gum resins and related phytopharmaceuticals by high-performance liquid chromatography. Identification of lupeolic acid, a novel pentacyclic triterpene. J Chromatogr B 2003, 791:21-30.
22. Mathe C, Archier P, Nehme L, Vieillescazes C. The study of nabataean organic residues from Madâ'in Sâlih, ancient hegra, by gas chromatography-mass spectrometry. Archaeometry 2009, 51:626-636.
23. Mathe C, Culioli G, Archier P, Vieillescazes C. High-performance liquid chromatographic analysis of triterpenoids in commercial frankincense. Chromatographia 2004, 60:493-499.
24. Culioli G, Mathe C, Archier P, Vieillescazes C. A lupane triterpene from frankincense (Boswellia sp., Burseraceae). Phytochemistry 2003, 62:537-541. 10.1016/S0031-9422(02)00538-1, 12560022.
25. Pardhy R, Bhattacharyya S. Tetracyclic triterpene acids from the resin of Boswellia serrata Roxb. Indian J Chem 1978, 16:174-175.
26. Singh T, Bhakuni R. A new euphane triterpene and a lipid diester from oleo-gum resin of Boswellia serrata. Indian J Chem 2006, 45:976-979.
27. Mathe C, Connan J, Archier P, Mouton M, Vieillescazes C. Analysis of Frankincense in Archaeological Samples by Gas chromatography-mass spectrometry. Annali di chimica 2007, 97:433-445. 10.1002/adic.200790029, 17867531.
28. Fattorusso E, Santacroce C, Xaasan CF. Dammarane triterpenes from the resin of Boswellia freerana. Phytochemistry 1985, 24:1035-1036.
29. Badria FA, Mikhaeil BR, Maatooq GT, Amer MMA. Immunomodulatory triterpenoids from the oleogum resin of Boswellia carterii Birdwood. ZEITSCHRIFT FUR NATURFORSCHUNG C 2003, 58:505-516.
30. Hairfield E, Hairfield H, McNair H. GC, GC/MS, and TLC of β-Boswellic Acid and O-Acetyl-β-Boswellic Acid from B. serrate, B. carteii, and B. papyrifera. J Chromatogr Sci 1989, 27:127-133.
31. Shen T, Lou HX. Bioactive constituents of myrrh and frankincense, two simultaneously prescribed gum resins in Chinese traditional medicine. Chem Biodivers 2008, 5:540-553. 10.1002/cbdv.200890051, 18421746.
32. Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon H. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 1992, 261:1143-1146.
33. Gayathri B, Manjula N, Vinaykumar K, Lakshmi B, Balakrishnan A. Pure compound from Boswellia serrata extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNFα, IL-1β, NO and MAP kinases. Int Immunopharmacol 2007, 7:473-482. 10.1016/j.intimp.2006.12.003, 17321470.
34. Akihisa T, Tabata K, Banno N, Tokuda H, Nishihara R, Nakamura Y, Kimura Y, Yasukawa K, Suzuki T. Cancer chemopreventive effects and cytotoxic activities of the triterpene acids from the resin of Boswellia carteri. Biol Pharm Bull 2006, 29:1976-1979. 10.1248/bpb.29.1976, 16946522.
35. Mahajan B, Taneja S, Sethi V, Dhar K. Two triterpenoids from Boswellia serrata gum resin. Phytochemistry 1995, 39:453-455.
36. Bhushan S, Kumar A, Malik F, Andotra SS, Sethi VK, Kaur IP, Taneja SC, Qazi GN, Singh J. A triterpenediol from Boswellia serrata induces apoptosis through both the intrinsic and extrinsic apoptotic pathways in human leukemia HL-60 cells. Apoptosis 2007, 12:1911-1926. 10.1007/s10495-007-0105-5, 17636381.
37. Stacey R, Cartwright C, McEwan C. Chemical characterization of ancient mesoamerican 'copal'resins: preliminary results. Archaeometry 2006, 48:323-340.
38. Tausch L, Henkel A, Siemoneit U, Poeckel D, Kather N, Franke L, Hofmann B, Schneider G, Angioni C, Geisslinger G. Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense. J Immunol 2009, 183:3433-3442. 10.4049/jimmunol.0803574, 19648270.
39. Schweizer S, von Brocke AFW, Boden SE, Bayer E, Ammon HPT, Safayhi H. Workup-dependent formation of 5-lipoxygenase inhibitory boswellic acid analogues. J Nat Prod 2000, 63:1058-1061. 10.1021/np000069k, 10978197.
40. Wang F, Li ZL, Cui HH, Hua HM, Jing YK, Liang SW. Two new triterpenoids from the resin of Boswellia carterii. J Asian Nat Prod Res 2011, 13:193-197. 10.1080/10286020.2010.548808, 21409679.
41. Sailer ER, Subramanian LR, Rall B, Hoernlein RF, Ammon H, Safayhi H. Acetyl-11-keto-β-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol 2012, 117:615-618.
42. Chashoo G, Singh SK, Mondhe DM, Sharma PR, Andotra SS, Shah BA, Taneja SC, Saxena AK. Potentiation of the antitumor effect of 11-keto-β-boswellic acid by its 3-α-hexanoyloxy derivative. Eur J Pharmacol 2011, 668:390-400. 10.1016/j.ejphar.2011.07.024, 21821018.
43. Kumar A, Shah BA, Singh S, Hamid A, Singh SK, Sethi VK, Saxena AK, Singh J, Taneja SC. Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs. Bioorg Med Chem Lett 2012, 22:431-435. 10.1016/j.bmcl.2011.10.112, 22123322.
44. Belsner K, Büchele B, Werz U, Syrovets T, Simmet T. Structural analysis of pentacyclic triterpenes from the gum resin of Boswellia serrata by NMR spectroscopy. Magn Reson Chem 2003, 41:115-122.
45. Dzubak P, Hajduch M, Vydra D, Hustova A, Kvasnica M, Biedermann D, Markova L, Urban M, Sarek J. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep 2006, 23:394-411. 10.1039/b515312n, 16741586.
46. Morikawa T, Oominami H, Matsuda H, Yoshikawa M. New terpenoids, olibanumols D-G, from traditional Egyptian medicine olibanum, the gum-resin of Boswellia carterii. J Nat Med 2011, 65:129-134. 10.1007/s11418-010-0472-z, 20953724.
47. Büchele B, Simmet T. Analysis of 12 different pentacyclic triterpenic acids from frankincense in human plasma by high-performance liquid chromatography and photodiode array detection. J Chromatogr B 2003, 795:355-362.
48. Buchele B, Zugmaier W, Estrada A, Genze F, Syrovets T, Paetz C, Schneider B, Simmet T. Characterization of 3α-Acetyl-11-keto-α-boswellic Acid, a Pentacyclic Triterpenoid Inducing Apoptosis in vitro and in vivo. Planta Med 2006, 72:1285. 10.1055/s-2006-951680, 17022003.
49. Verhoff M, Seitz S, Northoff H, Jauch J, Schaible AM, Werz O. A novel C (28)-hydroxylated lupeolic acid suppresses the biosynthesis of eicosanoids through inhibition of cytosolic phospholipase A2. Biochem Pharmacol 2012, 84:681-691. 10.1016/j.bcp.2012.06.016, 22732453.
50. Banno N, Akihisa T, Yasukawa K, Tokuda H, Tabata K, Nakamura Y, Nishimura R, Kimura Y, Suzuki T. Anti-inflammatory activities of the triterpene acids from the resin of Boswellia carteri. J Ethnopharmacol 2006, 107:249. 10.1016/j.jep.2006.03.006, 16621377.
51. Boden SE, Schweizer S, Bertsche T, Düfer M, Drews G, Safayhi H. Stimulation of leukotriene synthesis in intact polymorphonuclear cells by the 5-lipoxygenase inhibitor 3-oxo-tirucallic acid. Mol Pharmacol 2001, 60:267-273.
52. Aksamija A, Mathe C, Vieillescazes C. Liquid chromatography of triterpenic resins after derivatization with dansyl chloride. J Liq Chrom Relat Tech 2012, 35:1222-1237.
53. VRao C, MR Patlolla J. Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects. Curr Pharm Biotechnol 2012, 13:147-155. 10.2174/138920112798868719, 21466427.
54. Ammon H, Safayhi H, Mack T, Sabieraj J. Mechanism of antiinflammatory actions of curcumine and boswellic acids. J Ethnopharmacol 1993, 38:105-112. 10.1016/0378-8741(93)90005-P, 8510457.
55. Mothana RAA, Hasson SS, Schultze W, Mowitz A, Lindequist U. Phytochemical composition and in vitro antimicrobial and antioxidant activities of essential oils of three endemic Soqotraen Boswellia species. Food Chem 2011, 126:1149-1154.
56. Laszczyk MN. Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med 2009, 75:1549. 10.1055/s-0029-1186102, 19742422.
57. Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation. Proc Natl Acad Sci 1994, 91:2046-2050. 10.1073/pnas.91.6.2046, 43306, 7510883.
58. Bishnoi M, Patil CS, Kumar A, Kulkarni SK. Protective effects of nimesulide (COX Inhibitor), AKBA (5-LOX Inhibitor), and their combination in aging-associated abnormalities in mice. Methods Find Exp Clin Pharmacol 2005, 27:465-470. 10.1358/mf.2005.27.7.920929, 16258590.
59. Franceschi VR, Krokene P, Christiansen E, Krekling T. Anatomical and chemical defenses of conifer bark against bark beetles and other pests. New Phytol 2005, 167:353-376. 10.1111/j.1469-8137.2005.01436.x, 15998390.
60. Park YS, Lee JH, Harwalkar JA, Bondar J, Safayhi H, Golubic M. Acetyl-11-keto-boswellic acid (AKBA) is cytotoxic for meningioma cells and inhibits phosphorilation of the extracellular-signal regulated kinase 1 and 2. Adv Exp Med Biol 2002, 507:387-396.
61. Liu JJ, Nilsson T, Oredsson S, Badmaev V, Zhao WZ, Duan RD. Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis 2002, 23:2087-2093. 10.1093/carcin/23.12.2087, 12507932.
62. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J Biol Chem 1996, 271:33157-33160. 10.1074/jbc.271.52.33157, 8969167.
63. Pouliot M, Gilbert C, Borgeat P, Poubelle PE, Bourgoin S, Créminon C, Maclouf J, Mccoll SR, Naccache PH. Expression and activity of prostaglandin endoperoxide synthase-2 in agonist-activated human neutrophils. FASEB J 1998, 12:1109-1123.
64. Fennerty MB. NSAID-related gastrointestinal injury. Evidence-based approach to a preventable complication. Postgrad Med 2001, 110:87.
65. Cuzzolin L, Dal Cerè M, Fanos V. NSAID-induced nephrotoxicity from the fetus to the child. Drug Saf 2001, 24:9-18. 10.2165/00002018-200124010-00002, 11219488.
66. Cao H, Yu R, Choi Y, Ma ZZ, Zhang H, Xiang W, Lee DYW, Berman BM, Moudgil KD, Fong HHS. Discovery of cyclooxygenase inhibitors from medicinal plants used to treat inflammation. Pharmacol Res 2010, 61:519-524. 10.1016/j.phrs.2010.02.007, 2860736, 20188172.
67. Siemoneit U, Hofmann B, Kather N, Lamkemeyer T, Madlung J, Franke L, Schneider G, Jauch J, Poeckel D, Werz O. Identification and functional analysis of cyclooxygenase-1 as a molecular target of boswellic acids. Biochem Pharmacol 2008, 75:503-513. 10.1016/j.bcp.2007.09.010, 17945191.
68. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci 2004, 75:639-654. 10.1016/j.lfs.2003.10.042, 15172174.
69. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol 2007, 8:49-62. 10.1038/nrm2083, 17183360.
70. Li XX, Stark GR. NF kappa B-dependent signaling pathways. Exp Hematol 2002, 30:285-296. 10.1016/S0301-472X(02)00777-4, 11937262.
71. Xu T, Li D, Jiang D. Targeting Cell Signaling and Apoptotic Pathways by Luteolin: Cardioprotective Role in Rat Cardiomyocytes Following Ischemia/Reperfusion. Nutrients 2012, 4:2008-2019. 10.3390/nu4122008, 3546619, 23235403.
72. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Investig 2001, 107:7-11. 10.1172/JCI11830, 198552, 11134171.
73. Henkel A, Kather N, Mönch B, Northoff H, Jauch J, Werz O. Boswellic acids from frankincense inhibit lipopolysaccharide functionality through direct molecular interference. Biochem Pharmacol 2012, 83:115-121. 10.1016/j.bcp.2011.09.026, 22001311.
74. Poeckel D, Tausch L, Kather N, Jauch J, Werz O. Boswellic acids stimulate arachidonic acid release and 12-lipoxygenase activity in human platelets independent of Ca2+ and differentially interact with platelet-type 12-lipoxygenase. Mol Pharmacol 2006, 70:1071-1078. 10.1124/mol.106.024836, 16788089.
75. Sailer ER, Hoernlein R, Ammon H, Safayhi H. Structure-activity relationships of the nonredox-type non-competitive leukotriene biosynthesis inhibitor acetyl-11-keto-β-boswellic acid. Phytomedicine 1996, 3:73-74. 10.1016/S0944-7113(96)80014-6, 23194865.
76. Safayhi H, Sailer E, Ammon H. 5-Lipoxygenase inhibition by acetyl-11-keto-β-boswellic acid (AKBA) by a novel mechanism. Phytomedicine 1996, 3:71-72. 10.1016/S0944-7113(96)80013-4, 23194864.
77. Safayhi H, Rall B, Sailer E-R, Ammon HPT. Inhibition by boswellic acids of human leukocyte elastase. J Pharmacol Exp Ther 1997, 281:460-463.
78. Vitor C, Figueiredo C, Hara D, Bento A, Mazzuco T, Calixto J. Therapeutic action and underlying mechanisms of a combination of two pentacyclic triterpenes, α-and β-amyrin, in a mouse model of colitis. Br J Pharmacol 2009, 157:1034-1044. 10.1111/j.1476-5381.2009.00271.x, 2737662, 19508397.
79. Cota BB, Johann S, Oliveira DM, Siqueira EP, Souza-Fagundes EM, Cisalpino PS, Alves T, Zani CL. Biological potential of Stillingia oppositifolia. Revista Brasileira de Farmacognosia 2011, 21:70-77.
80. Yoshikawa M, Morikawa T, Oominami H, Matsuda H. Absolute stereostructures of olibanumols A, B, C, H, I, and J from olibanum, gum-resin of Boswellia carterii, and inhibitors of nitric oxide production in lipopolysaccharide-activated mouse peritoneal macrophages. Chem Pharm Bull 2009, 57:957-964. 10.1248/cpb.57.957, 19721256.
81. Na M, Kim BY, Osada H, Ahn JS. Inhibition of protein tyrosine phosphatase 1B by lupeol and lupenone isolated from Sorbus commixta. J Enzyme Inhib Med Chem 2009, 24:1056-1059. 10.1080/14756360802693312, 19548777.
82. Blain EJ, Ali AY, Duance VC. Boswellia frereana (frankincense) suppresses cytokine-induced matrix metalloproteinase expression and production of pro-inflammatory molecules in articular cartilage. Phytother Res 2009, 24:905-912.
83. Saleem M. Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett 2009, 285:109-115. 10.1016/j.canlet.2009.04.033, 2764818, 19464787.
84. Sun B, Karin M. NF-κB signaling, liver disease and hepatoprotective agents. Oncogene 2008, 27:6228-6244. 10.1038/onc.2008.300, 18931690.
85. Belakavadi M, Salimath BP. Mechanism of inhibition of ascites tumor growth in mice by curcumin is mediated by NF-kB and caspase activated DNase. Mol Cell Biochem 2005, 273:57-67. 10.1007/s11010-005-7717-2, 16013440.
86. Salminen A, Lehtonen M, Suuronen T, Kaarniranta K, Huuskonen J. Terpenoids: natural inhibitors of NF-κB signaling with anti-inflammatory and anticancer potential. Cell Mol Life Sci 2008, 65:2979-2999. 10.1007/s00018-008-8103-5, 18516495.
87. Murray G, Shaw D, Weaver R, McKay J, Ewen S, Melvin W, Burke M. Cytochrome P450 expression in oesophageal cancer. Gut 1994, 35:599-603. 10.1136/gut.35.5.599, 1374739, 8200549.
88. Chun YJ, Kim S. Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents. Med Res Rev 2003, 23:657-668. 10.1002/med.10050, 12939788.
89. Gregory CD, Dive C, Henderson S, Smith CA, Williams GT, Gordon J, Rickinson AB. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 1991, 349:612-614. 10.1038/349612a0, 1705663.
90. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys 2009, 486:95-102. 10.1016/j.abb.2009.01.018, 2749321, 19514131.
91. Lüschen S, Scherer G, Ussat S, Ungefroren H, Adam-Klages S. Inhibition of p38 mitogen-activated protein kinase reduces TNF-induced activation of NF-κB, elicits caspase activity, and enhances cytotoxicity. Exp Cell Res 2004, 293:196-206. 10.1016/j.yexcr.2003.10.009, 14729457.
92. Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg T, Grénman S, Isola J. Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000, 156:839-847. 10.1016/S0002-9440(10)64952-8, 1876829, 10702400.
93. Peter ME. Let-7 and miR-200 microRNAs. Cell Cycle 2009, 8:843-852. 10.4161/cc.8.6.7907, 2688687, 19221491.
94. Frank A, Unger M. Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A 2006, 1112:255-262. 10.1016/j.chroma.2005.11.116, 16364338.
95. Syrovets T, Büchele B, Gedig E, Slupsky JR, Simmet T. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIα. Mol Pharmacol 2000, 58:71-81.
96. Takahashi M, Sung B, Shen Y, Hur K, Link A, Boland CR, Aggarwal BB, Goel A. Boswellic acid exerts anti-tumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. Carcinogenesis 2012, 33:2441-2449. 10.1093/carcin/bgs286, 22983985.
97. Mitaine-Offer A-C, Hornebeck W, Sauvain M, Zèches-Hanrot M. Triterpenes and phytosterols as human leucocyte elastase inhibitors. Planta Med 2002, 68:930-932. 10.1055/s-2002-34929, 12391559.
98. Rout KK, Singh RK, Mishra SK. Simultaneous quantification of two bioactive lupane triterpenoids from Diospyros melanoxylon stem bark. J Planar Chromatogr - Mod TLC 2011, 24:376-380.
99. Tolstikova T, Sorokina I, Tolstikov G, Tolstikov A, Flekhter O. Biological activity and pharmacological prospects of lupane terpenoids: I. Natural lupane derivatives. Russ J Bioorg Chem 2006, 32:37-49.
100. Mutai C, Abatis D, Vagias C, Moreau D, Roussakis C, Roussis V. Cytotoxic lupane-type triterpenoids from Acacia mellifera. Phytochemistry 2004, 65:1159-1164. 10.1016/j.phytochem.2004.03.002, 15110698.
101. Wyllie AH. Apoptosis: an overview. Br Med Bull 1997, 53:451-465. 10.1093/oxfordjournals.bmb.a011623, 9374030.
102. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999, 15:269-290. 10.1146/annurev.cellbio.15.1.269, 10611963.
103. Liedtke C, Trautwein C. The role of TNF and Fas dependent signaling in animal models of inflammatory liver injury and liver cancer. Eur J Cell Biol 2012, 91:582-589. 10.1016/j.ejcb.2011.10.001, 22153863.
104. Jing Y, Nakajo S, Xia L, Nakaya K, Fang Q, Waxman S, Han R. Boswellic acid acetate induces differentiation and apoptosis in leukemia cell lines. Leuk Res 1999, 23:43-50. 10.1016/S0145-2126(98)00096-4, 9933134.
105. Bhushan S, Kakkar V, Pal HC, Guru SK, Kumar A, Mondhe D, Sharma P, Taneja SC, Kaur IP, Singh J. Enhanced Anticancer Potential of Encapsulated Solid Lipid Nanoparticles of TPD: A Novel Triterpenediol from Boswellia serrata. Mol Pharm 2013, 10:225-235. 10.1021/mp300385m, 23237302.
106. Syrovets T, Büchele B, Krauss C, Laumonnier Y, Simmet T. Acetyl-boswellic acids inhibit lipopolysaccharide-mediated TNF-α induction in monocytes by direct interaction with IκB kinases. J Immunol 2005, 174:498-506.
107. Syrovets T, Laumonnier Y, Büchele B, Simmet T. Pentacyclic triterpenoids from Boswellia serrata inhibit NFκB activation and TNF-α release. Implications for the treatment of chronic inflammatory diseases. Zeitschrift für Phytotherapie 2006, 27:33.
108. Raja AF, Ali F, Khan IA, Shawl AS, Arora DS, Shah BA, Taneja SC. Antistaphylococcal and biofilm inhibitory activities of acetyl-11-keto-β-boswellic acid from Boswellia serrata. BMC Microbiol 2011, 11:54. 10.1186/1471-2180-11-54, 3066120, 21406118.
109. Raja AF, Ali F, Khan IA, Shawl AS, Arora DS. Acetyl-11-keto-β-boswellic acid (AKBA); targeting oral cavity pathogens. BMC Res Notes 2011, 4:406. 10.1186/1756-0500-4-406, 3201914, 21992439.
110. Karima O, Riazi G, Khodadadi S, Yousefi R, Mahnam K, Mokhtari F, Cheraghi T, Moosavi-Movahedi AA. An in vitro study of the role of β-boswellic acid in the microtubule assembly dynamics. FEBS Lett 2012, 586:4132-4138. 10.1016/j.febslet.2012.10.007, 23098754.
111. Thring TS, Hili P, Naughton DP. Anti-collagenase, anti-elastase and anti-oxidant activities of extracts from 21 plants. BMC Complement Altern Med 2009, 9:27. 10.1186/1472-6882-9-27, 2728709, 19653897.
112. Akihisa T, Ogihara J, Kato J, Yasukawa K, Ukiya M, Yamanouchi S, Oishi K. Inhibitory effects of triterpenoids and sterols on human immunodeficiency virus-1 reverse transcriptase. Lipids 2001, 36:507-512. 10.1007/s11745-001-0750-4, 11432464.
113. Chevrier MR, Ryan AE, Lee DY-W, Zhongze M, Wu-Yan Z, Via CS. Boswellia carterii extract inhibits TH1 cytokines and promotes TH2 cytokines in vitro. Clin Diagn Lab Immunol 2005, 12:575-580. 1112084, 15879017.
114. Hüsch J, Gerbeth K, Fricker G, Setzer C, Zirkel J, Rebmann H, Schubert-Zsilavecz M, Abdel-Tawab M. Effect of Phospholipid-Based Formulations of Boswellia serrata Extract on the Solubility, Permeability, and Absorption of the Individual Boswellic Acid Constituents Present. J Nat Prod 2012, 75:1675-1682. 10.1021/np300009w, 23013292.
115. Posadzki P, Watson LK, Ernst E. Adverse effects of herbal medicines: an overview of systematic reviews. Clin Med 2013, 13:7-12. 10.7861/clinmedicine.13-1-7, 23472485.
116. Basch E, Boon H, Heerema TD, Foppo I, Hashmi S, Hasskarl J, Sollars D, Ulbricht C. Boswellia: An evidence-based systematic review by the natural standard research collaboration. J Herb Pharmacother 2004, 4:63-83.
117. Singh P, Chacko KM, Aggarwal ML, Bhat B, Khandal RK, Sultana S, Kuruvilla BT. A-90 Day Gavage Safety Assessment of Boswellia serrata in Rats. Toxicol Int 2012, 19:273-278. 10.4103/0971-6580.103668, 3532773, 23293466.
118. Devi PRS, Adilaxmamma K, Rao GS, Srilatha C, Raj MA. Safety Evaluation of Alcoholic Extract of Boswellia ovalifoliolata Stem-bark in Rats. Toxicol Int 2012, 19:115-120. 10.4103/0971-6580.97198, 3388753, 22778507.
119. Sontakke S, Thawani V, Pimpalkhute S, Kabra P, Babhulkar S, Hingorani L. Open, randomized, controlled clinical trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of knee. Indian J Pharmacol 2007, 39:27.
120. Gerbeth K, Hüsch J, Fricker G, Werz O, Schubert-Zsilavecz M, Abdel-Tawab M. In vitro metabolism, permeation, and brain availability of six major boswellic acids from Boswellia serrata gum resins. Fitoterapia 2013, 84:99-106.
121. Hüsch J, Bohnet J, Fricker G, Skarke C, Artaria C, Appendino G, Schubert-Zsilavecz M, Abdel-Tawab M. Enhanced absorption of boswellic acids by a lecithin delivery form (Phytosome®) of Boswellia extract. Fitoterapia 2013, 84:89-98.
122. Krüger P, Kanzer J, Hummel J, Fricker G, Schubert-Zsilavecz M, Abdel-Tawab M. Permeation of Boswellia extract in the Caco-2 model and possible interactions of its constituents KBA and AKBA with OATP1B3 and MRP2. Eur J Pharm Sci 2009, 36:275-284. 10.1016/j.ejps.2008.10.005, 19010411.
123. Karlina M, Pozharitskaya O, Kosman V, Ivanova S. Bioavailability of boswellic acids: in vitro/in vivo correlation. Pharm Chem J 2007, 41:569-572.
124. Raman G, Gaikar VG. Hydrotropic solubilization of boswellic acids from Boswellia serrata resin. Langmuir 2003, 19:8026-8032.
125. Krishna G, Chen KJ, Lin C-C, Nomeir AA. Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. Int J Pharm 2001, 222:77-89. 10.1016/S0378-5173(01)00698-6, 11404034.
126. Yee SY. In vitro permeability across Caco3 cells (colonic) can predict in vivo (small intestinal) absorption in man-Fact or myth. Pharm Res 1997, 14:763-766. 10.1023/A:1012102522787, 9210194.
127. Ammon HPT. Modulation of the immune system by Boswellia serrata extracts and boswellic acids. Phytomedicine 2010, 17:862-867. 10.1016/j.phymed.2010.03.003, 20696559.